Immuneering Corporation
NASDAQ:IMRX
2.34 (USD) • At close January 3, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | -94.419 | 0 | 94.419 | 0 | 0 | 0.038 | 0.094 | 0.184 | 0.19 | 0.482 | 0.66 | 0.748 | 0.665 | 0.683 | 0.481 | 0.483 |
| Cost of Revenue
| 0 | 0.175 | 0.188 | 0.185 | 0.196 | 0.194 | 0.19 | 157.964 | 0.019 | 0.048 | 0.091 | 0.206 | 0.219 | 0.319 | 0.409 | 0.473 | 0.315 | 0.237 | 0.255 |
| Gross Profit
| 0 | -0.175 | -0.188 | -94.604 | -0.196 | 94.225 | -0.19 | -157.963 | 0.019 | 0.046 | 0.093 | -0.017 | 0.263 | 0.341 | 0.339 | 0.192 | 0.368 | 0.244 | 0.228 |
| Gross Profit Ratio
| 0 | 0 | 0 | 1.002 | 0 | 0.998 | 0 | -346,411.013 | 0.496 | 0.492 | 0.505 | -0.088 | 0.546 | 0.517 | 0.453 | 0.288 | 0.539 | 0.507 | 0.472 |
| Reseach & Development Expenses
| 11.253 | 10.652 | 11.141 | 11.91 | 10.05 | 9.453 | 10.211 | 9.872 | 9.364 | 7.981 | 9.059 | 7.95 | 6.207 | 6.992 | 5.391 | 4.89 | 4.069 | 3.221 | 2.823 |
| General & Administrative Expenses
| 4.014 | 4.254 | 4.116 | 4.385 | 3.869 | 4.045 | 4.461 | 4.106 | 3.836 | 3.704 | 3.952 | 3.149 | 2.599 | 1.34 | 1.184 | 1.138 | 0.699 | 0.629 | 0.644 |
| Selling & Marketing Expenses
| 0 | 0 | -0.119 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 4.014 | 4.254 | 3.997 | 4.385 | 3.869 | 4.045 | 4.461 | 4.106 | 3.836 | 3.704 | 3.952 | 3.149 | 2.599 | 1.34 | 1.184 | 1.138 | 0.699 | 0.629 | 0.644 |
| Other Expenses
| 0.007 | -0.168 | 0.213 | 0.464 | 0.007 | 0.15 | 0.007 | 0.007 | 0.007 | -0.024 | 0.008 | -0.119 | -0.008 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 15.274 | 14.738 | 15.138 | 16.303 | 13.926 | 13.505 | 14.679 | 13.985 | 13.207 | 11.692 | 13.019 | 11.099 | 8.806 | 8.332 | 6.575 | 6.028 | 4.768 | 3.85 | 3.467 |
| Operating Income
| -15.274 | -14.914 | -15.326 | -16.302 | -13.926 | -13.505 | -14.68 | -13.985 | -13.188 | -11.646 | -12.926 | -11.116 | -8.543 | -7.991 | -6.236 | -5.836 | -4.4 | -3.607 | -3.239 |
| Operating Income Ratio
| 0 | 0 | 0 | 0.173 | 0 | -0.143 | 0 | -30,668.875 | -343.62 | -123.344 | -70.364 | -58.63 | -17.72 | -12.107 | -8.335 | -8.776 | -6.447 | -7.501 | -6.706 |
| Total Other Income Expenses Net
| 0.676 | 0.834 | 1.018 | 1.218 | 1.331 | 1.316 | 1.075 | 0.739 | 0.344 | 0.119 | 0.029 | 0.024 | 0.009 | 0.003 | 0.006 | 0 | 0.001 | 0.003 | 0.038 |
| Income Before Tax
| -14.597 | -14.08 | -14.308 | -15.084 | -12.595 | -12.189 | -13.604 | -13.246 | -12.844 | -11.527 | -12.897 | -11.092 | -8.534 | -7.987 | -6.23 | -5.836 | -4.399 | -3.604 | -3.201 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0.16 | 0 | -0.129 | 0 | -29,047.285 | -334.661 | -122.085 | -70.205 | -58.504 | -17.701 | -12.101 | -8.326 | -8.775 | -6.445 | -7.495 | -6.626 |
| Income Tax Expense
| 0 | -0 | -0 | -0.755 | -13,912.372 | -1.139 | -1,075.403 | -0.74 | -0.344 | -0.052 | -0.029 | -0.307 | -0.017 | 0.001 | 0 | 0.042 | -0 | 0.001 | 0 |
| Net Income
| -14.597 | -14.08 | -14.308 | -15.083 | -12.595 | -12.189 | 1,061.799 | -12.506 | -12.501 | -11.527 | -12.867 | -10.784 | -8.534 | -7.988 | -6.23 | -5.836 | -4.399 | -3.604 | -3.201 |
| Net Income Ratio
| 0 | 0 | 0 | 0.16 | 0 | -0.129 | 0 | -27,424.346 | -325.704 | -122.087 | -70.045 | -56.882 | -17.701 | -12.102 | -8.326 | -8.775 | -6.445 | -7.496 | -6.626 |
| EPS
| -0.49 | -0.47 | -0.49 | -0.52 | -0.43 | -0.43 | 40.16 | -0.47 | -0.47 | -0.44 | -0.49 | -0.42 | -0.47 | -0.33 | -0.46 | -0.43 | -0.33 | -0.27 | -0.24 |
| EPS Diluted
| -0.49 | -0.47 | -0.49 | -0.52 | -0.43 | -0.43 | 40.16 | -0.47 | -0.47 | -0.44 | -0.49 | -0.42 | -0.47 | -0.33 | -0.46 | -0.43 | -0.33 | -0.27 | -0.24 |
| EBITDA
| -15.177 | -14.816 | -15.228 | -14.898 | -13.841 | -13.419 | -14.596 | -13.901 | -13.113 | -11.584 | -12.696 | -11.039 | -8.497 | -7.953 | -6.196 | -5.762 | -4.383 | -3.588 | -3.224 |
| EBITDA Ratio
| 0 | 0 | 0 | 0.172 | 0 | -0.143 | 0 | -30,652.829 | -338.29 | -123.265 | -69.272 | -58.63 | -17.642 | -12.053 | -8.289 | -8.663 | -6.424 | -7.467 | -6.674 |